Skip to main content
Clinical Trials/NCT01192113
NCT01192113
Completed
Phase 4

An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection

Eisai Co., Ltd.23 sites in 1 country1,072 target enrollmentApril 2010

Overview

Phase
Phase 4
Intervention
Mecobalamin IV Injection
Conditions
Peripheral Neuropathy
Sponsor
Eisai Co., Ltd.
Enrollment
1072
Locations
23
Primary Endpoint
Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This is an open-label, randomized, multi-center clinical trial to evaluate the safety and efficacy in peripheral neuropathies patients treated with Mecobalamin Injection

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
May 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Group A: Diabetic Peripheral Neuropathy (IV)

Intervention: Mecobalamin IV Injection

Group B: Diabetic Peripheral Neuropathy (IM)

Intervention: Mecobalamin IM injection

Group C: Idiopathic Peripheral Neuropathy

Intervention: Mecobalamin IV or IM injection

Group D: Nutritional & Metabolic Peripheral Neuropathy

Intervention: Mecobalamin IV or IM injection

Group E: Compression Peripheral Neuropathy

Intervention: Mecobalamin IV or IM injection

Outcomes

Primary Outcomes

Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline

Time Frame: Baseline & End of Week 4

The TSS of peripheral neuropathy is used to score the intensity \& frequency of four symptoms in participants' feet/legs including: pain, burning sensation, numbness, and hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline (before treatment) scores were compared to scores after 4 weeks of treatment.

Rate of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline

Time Frame: Baseline and End of Week 4

TSS of peripheral neuropathy is used to score the intensity \& frequency of 4 symptoms in participants' feet/legs including: pain, burning sensation, numbness, hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline scores were compared to TSS decreasing rate after 4 weeks of treatment. Rate of TSS change = (TSS difference value/TSS before treatment)×100%.

Secondary Outcomes

  • Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline(Baseline and End of Week 2)
  • Rate of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline(Baseline and End of Week 2)
  • Value of the Neural Injury Score of the Lower Limbs (NIS-LL) Compared to Baseline(Baseline and End of Week 4)
  • Rate of the Neural Injury Score of the Lower Limbs (NIS-LL) Compared to Baseline(Baseline and End of Week 4)

Study Sites (23)

Loading locations...

Similar Trials